{"id":"NCT04688775","sponsor":"H. Lundbeck A/S","briefTitle":"Eptinezumab in Participants With Episodic Cluster Headache","officialTitle":"Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Delayed-Start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-23","primaryCompletion":"2023-06-14","completion":"2023-10-05","firstPosted":"2020-12-30","resultsPosted":"2024-08-09","lastUpdate":"2024-08-09"},"enrollment":231,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Cluster Headache, Episodic"],"interventions":[{"type":"DRUG","name":"Eptinezumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sequence 1: Eptinezumab Then Placebo","type":"EXPERIMENTAL"},{"label":"Sequence 2: Placebo Then Eptinezumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)","primaryOutcome":{"measure":"Change From Baseline in the Number of Weekly Cluster Headache (CH) Attacks, Averaged Over Weeks 1-2","timeFrame":"Baseline (Week 0), Weeks 1-2","effectByArm":[{"arm":"Eptinezumab","deltaMin":-4,"sd":0.93},{"arm":"Placebo","deltaMin":-4.6,"sd":0.89}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5048"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":120,"countries":["United States","Belgium","Czechia","Denmark","Estonia","Finland","France","Georgia","Germany","Greece","Italy","Japan","Netherlands","Norway","Portugal","Russia","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["40388178"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":112},"commonTop":["COVID-19","Nasopharyngitis","Constipation","Fatigue","Urinary tract infection"]}}